$21.605
-0.015[-0.07%]
At close: Apr 26
$21.605
0[0.00%]
After Hours: 4:00PM EDT
Silence Therapeutics
(NASDAQ:SLN)Silence Therapeutics Stock (NASDAQ:SLN), Analyst Ratings, Price Targets, Predictions
Silence Therapeutics PLC has a consensus price target of $49.4, established from looking at the 26 latest analyst ratings. The last 3 analyst ratings were released from Morgan Stanley, HC Wainwright & Co., and Morgan Stanley on April 22, 2024, March 15, 2024, and March 14, 2024. With an average price target of $55 between Morgan Stanley, HC Wainwright & Co., and Morgan Stanley, there's an implied 154.57% upside for Silence Therapeutics PLC from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
HC Wainwright & Co.
Chardan Capital
BMO Capital
Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Silence Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/22/2024 | SLN | Buy Now | Silence Therapeutics | $21.61 | 108.29% | Morgan Stanley | Michael Ulz | $45 → $45 | Maintains | Overweight | Get Alert |
| 03/15/2024 | SLN | Buy Now | Silence Therapeutics | $21.61 | 247.14% | HC Wainwright & Co. | Patrick Trucchio | → $75 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | SLN | Buy Now | Silence Therapeutics | $21.61 | 108.29% | Morgan Stanley | Michael Ulz | $29 → $45 | Maintains | Overweight | Get Alert |
| 03/14/2024 | SLN | Buy Now | Silence Therapeutics | $21.61 | 94.4% | Chardan Capital | Keay Nakae | $26 → $42 | Maintains | Buy | Get Alert |
| 03/13/2024 | SLN | Buy Now | Silence Therapeutics | $21.61 | 247.14% | HC Wainwright & Co. | Patrick Trucchio | $75 → $75 | Maintains | Buy | Get Alert |
| 02/22/2024 | SLN | Buy Now | Silence Therapeutics | $21.61 | 247.14% | HC Wainwright & Co. | Patrick Trucchio | → $75 | Reiterates | Buy → Buy | Get Alert |
| 01/31/2024 | SLN | Buy Now | Silence Therapeutics | $21.61 | 210.11% | BMO Capital | Kostas Biliouris | → $67 | Initiates | → Outperform | Get Alert |
| 01/18/2024 | SLN | Buy Now | Silence Therapeutics | $21.61 | 247.14% | HC Wainwright & Co. | Patrick Trucchio | → $75 | Reiterates | Buy → Buy | Get Alert |
| 11/17/2023 | SLN | Buy Now | Silence Therapeutics | $21.61 | 247.14% | HC Wainwright & Co. | Patrick Trucchio | $80 → $75 | Maintains | Buy | Get Alert |
| 08/17/2023 | SLN | Buy Now | Silence Therapeutics | $21.61 | 270.28% | HC Wainwright & Co. | Patrick Trucchio | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 08/17/2023 | SLN | Buy Now | Silence Therapeutics | $21.61 | 20.34% | Chardan Capital | Keay Nakae | → $26 | Reiterates | Buy → Buy | Get Alert |
| 07/24/2023 | SLN | Buy Now | Silence Therapeutics | $21.61 | -7.43% | Morgan Stanley | Michael Ulz | $20 → $20 | Reiterates | Overweight → Overweight | Get Alert |
| 07/17/2023 | SLN | Buy Now | Silence Therapeutics | $21.61 | -7.43% | Morgan Stanley | Michael Ulz | $20 → $20 | Reiterates | Overweight → Overweight | Get Alert |
| 06/26/2023 | SLN | Buy Now | Silence Therapeutics | $21.61 | -7.43% | Morgan Stanley | Michael Ulz | $20 → $20 | Reiterates | Overweight → Overweight | Get Alert |
| 06/20/2023 | SLN | Buy Now | Silence Therapeutics | $21.61 | -7.43% | Morgan Stanley | Michael Ulz | → $20 | Reiterates | → Overweight | Get Alert |
| 06/12/2023 | SLN | Buy Now | Silence Therapeutics | $21.61 | -7.43% | Morgan Stanley | Michael Ulz | → $20 | Reiterates | → Overweight | Get Alert |
| 05/18/2023 | SLN | Buy Now | Silence Therapeutics | $21.61 | 270.28% | HC Wainwright & Co. | Patrick Trucchio | → $80 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | SLN | Buy Now | Silence Therapeutics | $21.61 | 270.28% | HC Wainwright & Co. | Patrick Trucchio | → $80 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2023 | SLN | Buy Now | Silence Therapeutics | $21.61 | -7.43% | Morgan Stanley | Michael Ulz | → $20 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Silence Therapeutics (SLN)?
The latest price target for Silence Therapeutics (NASDAQ: SLN) was reported by Morgan Stanley on April 22, 2024. The analyst firm set a price target for $45.00 expecting SLN to rise to within 12 months (a possible 108.29% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Silence Therapeutics (SLN)?
The latest analyst rating for Silence Therapeutics (NASDAQ: SLN) was provided by Morgan Stanley, and Silence Therapeutics maintained their overweight rating.
When was the last upgrade for Silence Therapeutics (SLN)?
There is no last upgrade for Silence Therapeutics.
When was the last downgrade for Silence Therapeutics (SLN)?
There is no last downgrade for Silence Therapeutics.
When is the next analyst rating going to be posted or updated for Silence Therapeutics (SLN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Silence Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Silence Therapeutics was filed on April 22, 2024 so you should expect the next rating to be made available sometime around April 22, 2025.
Is the Analyst Rating Silence Therapeutics (SLN) correct?
While ratings are subjective and will change, the latest Silence Therapeutics (SLN) rating was a maintained with a price target of $45.00 to $45.00. The current price Silence Therapeutics (SLN) is trading at is $21.61, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.